References

1. Sekine, I.; Saijo, N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann. Oncol. 2001, 12 (11), 1515.25.

2. Mattison, L.K.; Soong, R.; Diasio, R.B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002, 3 (4), 485-492.

3. Van Kuilenburg, A.B.; Vreken, P.; Abeling, N.G.; Bakker, H.D.; Meinsma, R.; Van Lenthe, H.; De Abreu, R.A.; Smeitink, J.A.; Kayserili, H.; Apak, M.Y.; Christensen, E.; Holopainen, I.; Pulkki, K.; Riva, D.; Botteon, G.; Holme, E.; Tulinius, M.; Kleijer, W.J.; Beemer, F.A.; Duran, M.; Niezen-Koning, K.E.; Smit, G.P.; Jakobs, C.; Smit, L.M.; Van Gennip, A.; Van Kuilenburg, A.B.; Vreken, P.; Abeling, N.G. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet.

4. Ulrich, C.M.; Robien, K.; Sparks, R. Pharmacogenetics and folate metabolism—A promising direction. Pharmacogenomics 2002, 3 (3), 299-313.

5. Sibani, S.; Leclerc, D.; Weisberg, I.S.; O'Ferrall, E.; Watkins, D.; Artigas, C.; Rosenblatt, D.S.; Rozen, R. Characterization of mutations in severe methylenetet-rahydrofolate reductase deficiency reveals an FAD-responsive mutation. HumanMutat. 2003,21 (5), 509-520.

6. Heijmans, B.T.; Boer, J.M.; Suchiman, H.E.; Cornelisse,

C.J.; Westendorp, R.G.; Kromhout, D.; Feskens, E.J.; Slagboom, P.E. A common variant of the methylenete-trahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res. 2003, 63 (6), 12491253.

7. Ranganathan, P.; Eisen, S.; Yokoyama, W.M.; McLeod, H.L. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann. Rheum. Dis. 2003,62 (1), 4-9.

8. Jain, K.K. Personalized medicine. Curr. Opin. Mol. Ther. 2002, 4 (6), 548-558.

9. Dai, D.; Zeldin, D.C.; Blaisdell, J.A.; Chanas, B.; Coulter, S.J.; Ghanayem, B.I.; Goldstein, J.A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11 (7), 597-607.

10. Garcia-Martin, E.; Martinez, C.; Pizarro, R.M.; Garcia-Gamito, F.J.; Gullsten, H.; Raunio, H.; Agundez, J.A. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 2002, 71 (3), 196-204.

11. Pascussi, J.M.; Gerbal-Chaloin, S.; Drocourt, L.; Maurel, P.; Vilarem, M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 2003, 1619 (3), 243-253.

12. Yamamoto, N.; Tamura, T.; Kamiya, Y.; Sekine, I.; Kunitoh, H.; Saijo, N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J. Clin. Oncol.

13. Rowinsky, E.K.; Gilbert, M.R.; McGuire, W.P.; Noe,

D.A.; Grochow, L.B.; Forastiere, A.A.; Ettinger, D.S.; Lubejko, B.G.; Clark, B.; Sartorius, S.E. Sequences of taxol and cisplatin: A phase I and pharmacologic study. J. 17. Clin. Oncol. 1991, 9 (9), 1692-1703.

14. Fetell, M.R.; Grossman, S.A.; Fisher, J.D.; Erlanger,

B.; Rowinsky, E.; Stockel, J.; Piantadosi, S. Pre- 18. irradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous sys- 19. tem consortium. J. Clin. Oncol. 1997,15 (9), 3121-3128.

15. Gillies, J.; Hung, K.A.; Fitzsimons, E.; Soutar, R. Severe vincristine toxicity in combination with itraconazole. Clin. 20. Lab. Haematol. 1998, 20 (2), 123-124.

16. Villikka, K.; Kivisto, K.T.; Maenpaa, H.; Joensuu, H.; Neuvonen, P.J. Cytochrome P450-inducing antiepilep-tics increase the clearance of vincristine in patients with brain tumors. Clin.Pharmacol. Ther. 1999,66(6),589-593.

McLeod, H.L.; Siva, C. The thiopurine S-methyltransfer-ase gene locus—Implications for clinical pharmacogenom-ics. Pharmacogenomics 2002, 3 (1), 89-98. Tukey, R.H.; Strassburg, C.P. Human UDP-glucuronosyl-transferases: Metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581-616. Toffoli, G.; Cecchin, E.; Corona, G.; Boiocchi, M. Pharmacogenetics of irinotecan. Curr. Med. Chem. AntiCancer Agents 2003, 3 (3), 225-237. Bai, F.; Nakanishi, Y.; Kawasaki, M.; Takayama, K.; Yatsunami, J.; Pei, X.H.; Tsuruta, N.; Wakamatsu, K.; Hara, N. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 1996, 78 (3), 416 -421.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment